DAX24.760 -0,2%Est505.961 -0,3%MSCI World4.343 -0,1%Top 10 Crypto8,7800 +0,6%Nas22.547 -0,2%Bitcoin57.749 -0,7%Euro1,1830 -0,2%Öl68,56 ±-0,0%Gold4.915 -1,6%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Siemens 723610 Rheinmetall 703000 SAP 716460 Deutsche Telekom 555750 Siemens Energy ENER6Y NVIDIA 918422 Amazon 906866 Lufthansa 823212 Microsoft 870747 Bayer BAY001 DroneShield A2DMAA RENK RENK73 BASF BASF11 Mercedes-Benz Group (ex Daimler) 710000 Deutsche Bank 514000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX stabil -- Novo Nordisk setzt Aktienrückkauf fort -- Rheinmetall mit Großauftrag -- Steyr, Microsoft, TeamViewer, Norwegian, BHP, Ottobock, Warner Bros., NORMA im Fokus
Top News
Warner Bros.-Aktie steigt: Bieterschlacht zwischen Netflix und Paramount geht weiter Warner Bros.-Aktie steigt: Bieterschlacht zwischen Netflix und Paramount geht weiter
Pivotal-Point Nachverfolgung The Hershey (HSY): Schokoladen-Gigant besiegt die Kakao-Krise mit margenstarken Salty Snacks! Pivotal-Point Nachverfolgung The Hershey (HSY): Schokoladen-Gigant besiegt die Kakao-Krise mit margenstarken Salty Snacks!
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

I-MAB (spons. ADRs) Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
2,66 EUR +0,02 EUR +0,76 %
STU
3,21 USD -0,04 USD -1,08 %
BTT
I-MAB (spons. ADRs) jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone
Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2PVC6

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS44975P1030

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolNBP

I-MAB (spons. ADRs) Aktien News

DatumMeistgelesen
PR NewswireNovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO
PR NewswireNovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO
PR NewswireNovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward
Wer­bungI-MAB (spons. ADRs)-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireI-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB
PR NewswireI-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences
PR NewswireEverest Medicines Expands Strategic Investment in I-MAB
PR NewswireI-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member
PR NewswireI-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program
PR NewswireI-Mab to Participate at the Piper Sandler Healthcare Conference
PR NewswireI-Mab Reports Third Quarter 2024 Results
PR NewswireI-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer
PR NewswireI-Mab to Release Q3 2024 Financial Results on November 14, 2024
PR NewswireI-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024
PR NewswireI-Mab to Participate at the Truist Securities BioPharma Symposium
PR NewswireI-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024
PR NewswireI-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer
PR NewswireI-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates
PR NewswireI-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
PR NewswireI-Mab to Release 1H 2024 Financial Results on August 28, 2024
PR NewswireI-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC)
PR NewswireI-Mab Announces Leadership Transitions
PR NewswireI-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer
PR NewswireI-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers
PR NewswireI-Mab to Participate at the Jefferies Global Healthcare Conference
PR NewswireI-MAB Filed 2023 Annual Report on Form 20-F
PR NewswireI-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference
PR NewswireI-Mab Announces Closing of the Divestiture of Business Operations in China
PR NewswireI-Mab Reports Full Year 2023 Financial Results and Business Update
PR NewswireI-Mab Signs Agreement to Divest its Assets and Business Operations in China
PR NewswireI-Mab Announces Participation at Jefferies and Piper Conferences in November
PR NewswireFelzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)
PR NewswireI-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023
PR NewswireI-Mab Announces Phase 1 Data of Givastomig at ESMO 2023
PR NewswireI-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503
PR NewswireI-Mab Announces Upcoming Participation at September Conferences
PR NewswireI-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates
PR NewswireI-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023
PR NewswireI-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITC

I-MAB (spons. ADRs) News

I-MAB (spons. ADRs) News: auf dieser Seite finden Sie alle I-MAB (spons. ADRs) News und Nachrichten zur I-MAB (spons. ADRs) Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch I-MAB (spons. ADRs) News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um I-MAB (spons. ADRs) News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.